Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are widely used in the Republic of the Congo to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The market for these drugs has been growing steadily over the years due to several factors.
Customer preferences: Customers in the Republic of the Congo prefer bronchodilator drugs that are affordable and effective. They are more likely to choose generic drugs over branded ones due to the cost difference. However, they also value quality and safety, so they tend to choose drugs that are approved by the country's regulatory authorities.
Trends in the market: One of the major trends in the bronchodilator drugs market in the Republic of the Congo is the increasing prevalence of respiratory diseases. This is due to several factors such as air pollution, smoking, and poor living conditions. As a result, the demand for bronchodilator drugs has been increasing steadily over the years.Another trend in the market is the increasing availability of generic drugs. This has been driven by the government's efforts to make healthcare more affordable and accessible to the population. The government has been promoting the use of generic drugs by providing incentives to doctors and pharmacists who prescribe and dispense them.
Local special circumstances: The Republic of the Congo has a relatively small population and a low GDP per capita. This means that the market for bronchodilator drugs is relatively small compared to other countries in the region. However, the market has been growing steadily over the years due to the increasing prevalence of respiratory diseases.
Underlying macroeconomic factors: The Republic of the Congo is heavily dependent on oil exports, which account for the majority of its export earnings. However, the country has been facing economic challenges in recent years due to the decline in oil prices and the COVID-19 pandemic. This has led to a slowdown in economic growth and a reduction in government spending on healthcare. Despite these challenges, the market for bronchodilator drugs has remained resilient due to the increasing demand for these drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
